Harald G. Enzmann

Kurt Georg Kiesinger Allee 3
Bonn, NW 53175, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Analysis of a decade of post-authorisation studies for medicines approved by the EMA.

Analysis of a decade of post-authorisation studies for medicines approved by the EMA.

Journal: Nature reviews. Drug discovery

Published: June 10, 2026

Trends in EU regulatory assessment of oncology medicines.

Trends in EU regulatory assessment of oncology medicines.

Journal: ESMO open

Published: October 02, 2025

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.

Journal: Cancer treatment reviews

Published: June 13, 2025

Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.

Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.

Journal: The Lancet. Oncology

Published: February 19, 2025

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.

Journal: The oncologist

Published: January 16, 2023

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.

Journal: ESMO open

Published: March 02, 2022

Attention for sex in COVID-19 trials: a review of regulatory dossiers.

Attention for sex in COVID-19 trials: a review of regulatory dossiers.

Journal: BMJ global health

Published: December 02, 2021

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: HemaSphere

Published: September 07, 2021

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.

Journal: HemaSphere

Published: May 18, 2021

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.

Journal: HemaSphere

Published: April 20, 2021

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Journal: ESMO open

Published: March 10, 2021

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.

Journal: ESMO open

Published: March 09, 2021

Showing 1-12 of 48

Last Updated: 09/26/2026